Journey Medical (NASDAQ:DERM) and Eloxx Pharmaceuticals (NASDAQ:ELOX) Financial Survey

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and Journey Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$5.99 million	($15.29)	-1.23
Journey Medical	$61.86 million	2.99	-$11.43 million	($0.22)	-30.55

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eloxx Pharmaceuticals and Journey Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Journey Medical	-8.95%	-20.23%	-6.60%

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1864.08, meaning that its stock price is 186,508% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Eloxx Pharmaceuticals and Journey Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0	0	2	0	3.00
Journey Medical	1	1	2	0	2.25

Eloxx Pharmaceuticals currently has a consensus target price of $41.50, indicating a potential upside of 121.22%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 108.33%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than Journey Medical.

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Journey Medical shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats Journey Medical on 8 of the 12 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.